Abramson Cancer Center News


FDA Approves CAR T Therapy for Large B Cell Lymphoma Developed at University of Pennsylvania

The U.S. Food and Drug Administration (FDA) has expanded approval for a personalized cellular therapy developed at the University of Pennsylvania’s Abramson Cancer Center, this time for the treatment of adult patients with relapsed or refractory large B-Cell lymphoma after two or more lines of systemic therapy.

Read More

Recent News